Clinical Trial Update: Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sitaxsentan plus sildenafil versus sitaxsentan alone in pulmonary arterial hypertension was terminated. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• REVATIO (SILDENAFIL CITRATE)
• Thelin (sitaxentan)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2012-02-29